Tris Pharma
Dr. Cappuccino joined Tris in 2021, and as Chief Quality Officer is responsible for all aspects of Tris Quality & Compliance. Nick has over 40 years of experience in the pharmaceutical industry leading Quality and R&D teams as well as working with the US FDA and other global regulatory agencies at both a strategic policy level and at a tactical level for matters of Pharmaceutical Quality, GMP Compliance and Regulatory Affairs. Nick’s depth of experience includes senior leadership roles at Dr. Reddy’s Laboratories, Eagle Pharmaceuticals, Andrx Pharmaceuticals, Sandoz Inc. and Apotex, Inc. Prior to his advancement into leadership roles, Nick also worked for Sanofi (formerly Hoechst -Roussel) Pharmaceuticals, Schering-Plough and Geneva Pharmaceuticals. Nick currently serves as the Chair of the Science Committee for the International Generic and Biosimilar Medicines Association (IGBA) and represents IGBA on the ICH Management Committee and the ICH Assembly. Dr. Cappuccino holds a Ph.D. in Organic Chemistry from Stevens Institute of Technology, Hoboken, NJ, and an MBA from Fairleigh Dickinson University, Madison, NJ.
This person is not in any offices
Tris Pharma
1 followers
Tris Pharma, Inc. is one of the top five privately-owned specialty pharmaceutical companies in the U.S. with a focus on the development of pharmaceutical science and technology-based products. Specifically, we are engaged in research, development, manufacturing, and commercialization of both branded products and specialty generic products. We have more than a dozen solid and liquid products in the U.S. market based on our numerous NDAs and ANDAs and a rich and growing portfolio of more than 30 U.S. granted patents. Our commercialization success is driven by internal resources for our pediatric products and by licensing of our non-pediatric products to other companies.